June 2010 – Page 5 – Oral Cancer News

ASCO: Non-platinum regimen works in head, neck cancer

Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel non-platinum-based regimen was efficacious in recurrent or metastatic squamous cell head and neck cancer, researchers said. The combination of pemetrexed (Alimta) and bevacizumab (Avastin) yielded a response rate of 30% in a small single-arm trial, according to Athanassios Argiris, MD, of the University of Pittsburgh, and colleagues. The combination also increased the length of time before patients progressed, and increased median overall survival, Argiris and colleagues reported in a poster discussion session at the annual meeting of the American Society of Clinical Oncology here. Patients with recurrent or metastatic disease typically have a poor prognosis, the researchers said, with median survival between six and nine months with standard chemotherapy. But, in other research, adding the monoclonal antibody cetuximab (Erbitux) to platinum-based chemotherapy increased survival, they said. Bevacizumab is a monoclonal antibody that targets the vascular epithelial growth factor (VEGF), which is expressed in squamous cell head and neck cancer; high levels of VEGF correlate with poor outcome, they noted. The researchers hypothesized that the antibody might enhance the activity of pemetrexed, which is a multi-targeted antifolate indicated for malignant pleural mesothelioma and non-small cell lung cancer. To test the idea, they analyzed results of treating 37 patients given 500 mg/m2 of pemetrexed and 15 mg/kg of bevacizumab intravenously every 21 days until disease progression. Patients were also given folic acid and vitamin B12. The primary endpoint of the study was time to progression, they said, but the researchers [...]

Oral Cancer Foundation News Team - A2010-06-06T07:32:19-07:00June, 2010|Oral Cancer News|

ASCO: Antibody improves head and neck cancer results

Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel antibody improved outcomes for patients with advanced and inoperable squamous cell carcinoma of the head and neck, researchers reported. Combined with radiation or chemoradiation, the substance -- a fully humanized monoclonal antibody dubbed nimotuzumab -- significantly outperformed either modality alone in an open-label randomized trial, according to K. Govind Babu, MD, of Kidwai Memorial Institute of Oncology in Bangalore, India, and colleagues. At the same time, there was little serious toxicity -- such as debilitating skin rash -- attributed to the compound, the researchers reported in a poster discussion session at the annual meeting of the American Society of Clinical Oncology here. It's the first randomized study of the drug to show clinical benefit without the toxicities associated with similar antibodies, the researchers said. In general, neither radiation nor chemotherapy provides a good outcome for patients with inoperable stage III or IVa squamous cell carcinoma of the head and neck. However, substances such as cetuximab (Erbitux) that target the epidermal growth factor receptor (EGFR) -- overexpressed in such tumors -- have improved outcomes. Nimotuzumab, like cetuximab, targets EGFR, but is highly selective for tumor tissues, limiting toxicity, the researchers said. The study enrolled 92 patients, and 76 were evaluable for efficacy. They were treated with radiation or chemoradiation (with cisplatin), with or without nimotuzumab. The substance was given by intravenous infusion of 200 milligrams over a 60-minute period, once a week for six weeks. In group A -- [...]

Oral Cancer Foundation News Team - A2010-06-06T07:24:13-07:00June, 2010|Oral Cancer News|

Cancer will kill 13.2 million a year by 2030: U.N.

Source: www.medscape.com Author: Reuters Health Information Cancer will kill more than 13.2 million people a year by 2030, almost double the number who died from the disease in 2008, the United Nations' cancer research agency said on Tuesday. The International Agency for Research on Cancer (IARC) also said that almost 21.4 million new cases of the disease will be diagnosed annually in 2030. Launching a new database on global incidence of cancer in 2008, the latest year for which figures are available, the IARC said the burden of cancer was shifting from wealthier to poorer nations. "Cancer is neither rare anywhere in the world, nor confined to high-resource countries," it said in a statement. In total, 7.6 million people died of cancer in 2008 and there were an estimated 12.7 million new cases diagnosed. Around 56% of new cancer cases worldwide in 2008 were in developing countries and these regions also accounted for 63% of all cancer deaths, the data showed. IARC director Christopher Wild said the data represented the most accurate available assessment of the global burden of cancer and would help international health policy makers develop their responses. The most commonly diagnosed cancers worldwide in 2008 were lung cancer, with 1.61 million cases, breast cancer, with 1.38 million, and colorectal cancers, with 1.23 million. The most common causes of cancer death were lung (1.38 million), stomach (0.74 million) and liver cancers (0.69 million) The projection for annual death rates of 13.2 million and annual diagnosis of 21.4 million [...]

Oral Cancer Foundation News Team - A2010-06-04T16:30:39-07:00June, 2010|Oral Cancer News|

New report compares radiation approaches in head and neck cancer

Source: MedScape Today Author: Nick Mulcahy June 1, 2010 — Intensity-modulated radiation therapy (IMRT) for head and neck cancer leads to fewer cases of xerostomia, but has not yet been proven to be more successful than any other kind of radiation therapy in reducing tumors or improving survival, according to a new comparative-effectiveness review funded by the federal Agency for Healthcare Research and Quality (AHRQ). The review compares the effectiveness of 4 types of radiotherapy (IMRT, 3DCRT, 2DRT, and proton-beam therapy) in terms of tumor control, overall survival, adverse events, and quality-of-life issues. Many scientists consider IMRT to be theoretically better able to target cancerous cells while sparing healthy tissue than either 3DCRT or 2DRT, but more research is needed, the authors of the report point out. The report, entitled Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer, is authored by the Blue Cross and Blue Shield Association's Technology Evaluation Center Evidence-Based Practice Center. The late adverse effect of xerostomia, also known as dry mouth, is less common than in the past because the use of IMRT has allowed radiation oncologists to spare most patients' salivary glands from radiation as part of treatment planning, an expert recently told Medscape Oncology. Sparing salivary glands has become standard among clinicians who use IMRT, said Avraham Eisbruch, MD, professor of radiation oncology at the University of Michigan Medical School and Comprehensive Cancer Center in Ann Arbor. Dr. Eisbruch's comments came in the context of his study on the use of IMRT [...]

Charlotte Parker2010-06-04T16:26:20-07:00June, 2010|Oral Cancer News|

U.S. cigarette brands tops in cancer causing chemicals

Source: CNN Author: Miriam Falco Smokers of U.S. brand cigarettes may get more bang for their buck in the worst way according to a small study conducted by the Centers for Disease Control and Prevention. Researchers found U.S. made cigarettes contain more cancer-causing chemicals than some cigarettes brands made elsewhere around the world. “Not all cigarettes are made alike” says Dr. Jim Pirkle, deputy director for science at the CDC’s National Center for Environmental Health. He says this is the first study to show that “U.S. cigarettes have more of the major carcinogen [TSNAs] than foreign made cigarettes." TSNAs are “tobacco-specific nitrosamines,” the major cancer-causing substance in tobacco. 126 smokers in five cities – Waterloo, Ontario; Melbourne, Victoria (Australia); London, England, Buffalo, New York, and Minneapolis, Minnesota – were recruited for this study. They were between the ages of 18 and 55 and smoked at least 10 cigarettes a day for the past year and had been brand loyal for at least three months. The cigarettes smoked by the study recruits represented some of the more popular brands for each country including: Players light and DuMaurier in Canada; Marlboro, Newport Light, Camel Light in the U.S.; Peter Jackson and Peter Stuyvesant in Australia; and Benson & Hedges and Silk Cut Purple in the United Kingdom. Scientists analyzed more than 2,000 cigarette butts to get the data they are reporting today, says Pirkle. When researchers compared cigarette brands in the U.S. to those in Canada and Australia, they found three times higher [...]

Charlotte Parker2010-06-04T13:06:10-07:00June, 2010|Oral Cancer News|

Oral cancer doesn’t silence North Carolina man

Source: The Cherokee Scout Author: Lizz Harold Marble – Switching out one form of tobacco for another, Rick Miller, 44, learned how to quit smoking and dipping the hard way. Miller went to a doctor in March to see if an ulcer inside his mouth could be removed. He expected a round of antibiotics or oral surgery. He figured he would be back to dipping as usual after it was taken care of. “I really didn’t have any symptoms. I got an ulcer underneath my tongue. They thought it was all it was,” Miller said. Miller’s wife, Nicolia, did what most people do when they suspect they have an ailment. She went online and did an Internet search. After doing her own research, she was convinced it was mouth cancer, and Miller decided to see a specialist to see if their suspicions were correct. “Everything happened so fast after that,” Miller said. Informed by the specialist that he had oral cancer, he was immediately set up with a chemotherapy and radiation doctor. The father of four, two who are twin toddlers, had to undergo bouts of chemotherapy – including days where it was pumping into him everyday. From dipping to smoking Eight years ago, he stopped a 21-year smoking habit and began dipping tobacco. After more than 30 years of combined tobacco use, Miller has been forced to give up his addiction. “I gave up smoking and needed something to fill the void,” Miller said. He said he got a [...]

Charlotte Parker2010-06-03T15:55:07-07:00June, 2010|Oral Cancer News|

Big Tobacco Files Lawsuit Over Anti-Smoking Ads

Source: Gothamist Author: John Del Signore A Board of Health directive could soon require any retailers selling cigarettes to display graphic warning signs (like the sample here) about the dangers of smoking, plus information on where to seek help quitting. But that would violate their First Amendment rights by focring them to "undertake graphic advocacy on behalf of the city," according to a lawsuit filed in Manhattan Supreme Court today by cigarette manufacturers' R.J. Reynolds, Philip Morris and Lorillard, along with two Queens convenience stores and two retail groups. The signs, which vividly depict the insalubrious effects of smoking on various parts of the human body (think mouth cancer and heart disease), "do not describe the risks of smoking in purely factual terms," the lawsuit claims.Furthermore, "The mandated signs crowd out other advertisements and otherwise dominate the point of sale in many smaller establishments, to the exclusion of merchandise or other messages chosen by the store owners. The signs thus deprive retailers of the limited space available for communicating with their customers and thereby restrict their speech." Say, it's nice to see Big Tobacco sticking up for the little guy, innit? In a statement, the Health Department says: Tobacco is an addictive drug that kills some 7,500 New Yorkers every year. It disables many more. Yet studies show that many smokers are still unaware of the full risks that smoking poses. By requiring cigarette vendors to post warning signs at the point of sale in retail outlets, New York City is trying to alert [...]

Charlotte Parker2010-06-03T15:40:35-07:00June, 2010|Oral Cancer News|

Free oral cancer screenings offered June 5th at NASCAR Event, at Nashville SuperSpeedway

Source: The Tennessean Author: Staff One person dies each hour of each day from oral cancer in the United States, but it only takes a three-minute oral exam to potentially save a life. On June 5, local dentists and hygienists will gather at the Nashville SuperSpeedway for the NASCAR Nationwide Series, to conduct free oral cancer screenings for the general public. The event is being sponsored by the Oral Cancer Foundation, to educate others about the importance of prevention and early detection through check-ups and awareness of important warning signs. The free exams will be conducted from 2-6 p.m. at the Speedway. Approximately 35,000 people in the U.S. will be newly diagnosed with oral cancer in 2010, which includes mouth cancer, tongue cancer and throat cancer. When found early, there is an 80 to 90 percent survival rate. However, due to a lack of public awareness, the majority of cases are found as late-stage cancers that can be killers. The Oral Cancer Foundation is a national public service, non-profit entity designed to reduce suffering and save lives through prevention, education, research, advocacy, and support activities. Check outwww.oralcancerfoundation.org to learn more about risk factors, signs and symptoms, treatments, current research and up-to-date oral cancer related news, among other important information. A free patient/survivor discussion forum is also open to the public, where those currently fighting oral cancer can gain insights and inspiration from those who have been there before them. The NASCAR Nationwide Series returns to Nashville Superspeedway on June 5 [...]

Charlotte Parker2010-06-03T16:00:35-07:00June, 2010|OCF In The News, Oral Cancer News|